Search Result

Results for "

ABL1 kinase

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Bcr-Abl (31) AAK1 (1) Akt (3) Apoptosis (4) Aurora Kinase (4) c-Kit (3) c-Met/HGFR (1) CaMK (1) CDK (2) Cyclin G-associated Kinase (GAK) (1) Discoidin Domain Receptor (2) DYRK (1) EGFR (1) Ephrin Receptor (1) Ferroptosis (2) FLT3 (4) GSK-3 (1) Isotope-Labeled Compounds (1) JAK (3) LIM Kinase (LIMK) (2) LRRK2 (1) MAP4K (1) MAPKAPK2 (MK2) (1) Microtubule/Tubulin (1) MNK (1) p38 MAPK (1) PDGFR (4) Prion Protein (3) PROTACs (3) Reference Standards (2) RET (1) Salt-inducible Kinase (SIK) (2) Src (3) STAT (6) ULK (2) α-synuclein (1)
By Research Areas:	Cancer (28) Infection (2) Inflammation/Immunology (1) Metabolic Disease (1) Neurological Disease (5)

By Targets:

Bcr-Abl (31)

AAK1 (1)

Akt (3)

Apoptosis (4)

Aurora Kinase (4)

c-Kit (3)

c-Met/HGFR (1)

CaMK (1)

CDK (2)

Cyclin G-associated Kinase (GAK) (1)

Discoidin Domain Receptor (2)

DYRK (1)

EGFR (1)

Ephrin Receptor (1)

Ferroptosis (2)

FLT3 (4)

GSK-3 (1)

Isotope-Labeled Compounds (1)

JAK (3)

LIM Kinase (LIMK) (2)

LRRK2 (1)

MAP4K (1)

MAPKAPK2 (MK2) (1)

Microtubule/Tubulin (1)

MNK (1)

p38 MAPK (1)

PDGFR (4)

Prion Protein (3)

PROTACs (3)

Reference Standards (2)

RET (1)

Salt-inducible Kinase (SIK) (2)

Src (3)

STAT (6)

ULK (2)

α-synuclein (1)

By Research Areas:

Cancer (28)

Infection (2)

Inflammation/Immunology (1)

Metabolic Disease (1)

Neurological Disease (5)

Inhibitors & Agonists

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Targets Recommended: Bcr-Abl

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-15728

Radotinib 1 Publications Verification IY-5511	Bcr-Abl Apoptosis STAT JAK Prion Protein	Infection Neurological Disease Cancer
Radotinib (IY-5511) is an orally active and BBB-permeable selective tyrosine kinase *Bcr-Abl1* inhibitor with an IC₅₀ of 34 nM. Radotinib has anti-prion and anti-tumor activities. Radotinib can inhibit the proliferation, induce cell cycle arrest and apoptosis of tumor cells . Radotinib can be used in the research of cancer such as chronic myeloid leukemia and multiple myeloma, as well as neurodegenerative diseases such as prion diseases .

HY-137460

Vodobatinib 2 Publications Verification K0706	Bcr-Abl	Cancer
Vodobatinib (K0706) is a potent, third generation and orally active Bcr-Abl1 tyrosine kinase inhibitor with an IC₅₀ of 7 nM. Vodobatinib exhibits activity against most BCR-ABL1 point mutants, and has no activity against BCR-ABL1T315I. Vodobatinib can be used for chronic myeloid leukemia (CML) research . Vodobatinib is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-148794

Risvodetinib IkT-148009	c-Met/HGFR Bcr-Abl	Neurological Disease Cancer
Risvodetinib (IkT-148009) is an orally active, selective and brain-penetrant protein tyrosine kinase inhibitor, displaying excellent target efficacy against *c-Abl1, c-Abl2/Arg* with IC₅₀ values of 33 nM, 14 nM, respectively. Risvodetinib suppresses *c-Abl* activation and substantially protects dopaminergic neurons from degeneration in mouse models of both inherited and sporadic Parkinson’s disease (PD), which is promising for research in the field of PD .

HY-13072

Cenisertib 1 Publications Verification AS-703569; R-763	Aurora Kinase Bcr-Abl Akt STAT FLT3	Cancer
Cenisertib (AS-703569) is an ATP-competitive multi-kinase inhibitor that blocks the activity of *Aurora-kinase-A/B, ABL1, AKT, STAT5 and FLT3*. Cenisertib induces major growth-inhibitory effects by blocking the activity of several different molecular targets in neoplastic mast cells (MC). Cenisertib inhibits tumor growth in xenograft models of pancreatic, breast, colon, ovarian, and lung tumors and leukemia .

HY-148061

DB1113	PROTACs Bcr-Abl CDK Salt-inducible Kinase (SIK) Cyclin G-associated Kinase (GAK) MAP4K MAPKAPK2 (MK2) Ferroptosis ULK LIM Kinase (LIMK)	Cancer
DB1113 (Example 24) is a bifunctional compound targeted protein degradation of kinases. DB1113 degrades ABL1, ABL2, BLK, CDK11B, CDK4, CSK, EPHA3, FER, GAK, LIMK1, MAP3K20, MAP4K1, MAP4K2, MAP4K3, MAP4K5, MAPK14, MAPK7, MAPK8, MAPK9, MAPKAPK2, MAPKAPK3, NLK, PDIK1L, PTK2B, RIPK1, RPS6KA1, RPS6KA3, SIK2, SIK3, STK35, TNK2, and ULK1. DB1113 can be used for research of disease or disorder mediated by aberrant kinase activity .

HY-W143698

PDGFRα kinase inhibitor 2	Bcr-Abl c-Kit PDGFR	Cancer
PDGFRα kinase inhibitor 2 (compound 1), an Imatinib (HY-15463) analogue, is a covalent and irreversible kinase inhibitor with IC₅₀s of 6.95 μM, 2.45 μM, 1.39 μM for *ABL1* wt, KIT wt, PDGFRR wt .

HY-103032

Multi-kinase inhibitor 1	PDGFR c-Kit Bcr-Abl	Cancer
Multi-kinase inhibitor 1 is a potent *multi-kinase* inhibitor. Multi-kinase inhibitor 1 has the potential for diseases or disorders associated with abnormal or deregulated tyrosine kinase activity, particularly diseases associated with the activity of PDGF-R, c-Kit and *Bcr-abl* .

HY-E70634

**ABL1 E255K Recombinant Human Active Protein Kinase**	Bcr-Abl	Cancer
The emergence of mutations in the BCR::ABL1 kinase domain (KD) impairs Imatinib Mesylate (HY-50946) binding capacity, thus contributing to Imatinib Mesylate resistance. Identification of these mutations is important for treatment decisions and precision medicine in chronic myeloid leukaemia (CML). ABL1 E255K Recombinant Human Active Protein Kinase is a recombinant ABL1 E255K protein that can be used to study ABL1 E255K-related functions .

HY-148063

DB0614	PROTACs AAK1 Aurora Kinase CaMK CDK Ferroptosis Salt-inducible Kinase (SIK) LIM Kinase (LIMK) ULK	Metabolic Disease
DB0614 is a PROTAC based on Cereblon ligand, which is a selective and potent targeted protein degrader of NEK9 inhibitor. DB0614 can degrade ABL1, ABL2, BLK, CDK11B, CDK4, CSK, EPHA3, FER, GAK, LIMK1, MAP3K20, MAP4K1, MAP4K2, MAP4K3, MAP4K5, MAPK14, MAPK7, MAPK8, MAPK9, MAPKAPK2, MAPKAPK3, NLK, PDIK1L, PTK2B, RIPK1, RPS6KA1, RPS6KA3, SIK2, SIK3, STK35, TNK2 and ULK1. DB0614 can be used for research of disease or disorder mediated by aberrant kinase activity .(Blue: Thalidomide-4-OH (HY-103596), Black: linker, Pink: FLT3-IN-17 (HY-148070))

HY-E70639

**ABL1 Q252H Recombinant Human Active Protein Kinase**	Bcr-Abl	Cancer
The emergence of mutations in the BCR::ABL1 kinase domain (KD) impairs Imatinib Mesylate (HY-50946) binding capacity, thus contributing to Imatinib Mesylate resistance. Identification of these mutations is important for treatment decisions and precision medicine in chronic myeloid leukaemia (CML). ABL1 Q252H Recombinant Human Active Protein Kinase is a recombinant ABL1 Q252H protein that can be used to study ABL1 Q252H-related functions .

HY-E70640

**ABL1 T315I Recombinant Human Active Protein Kinase**	Bcr-Abl	Cancer
The emergence of mutations in the BCR::ABL1 kinase domain (KD) impairs Imatinib Mesylate (HY-50946) binding capacity, thus contributing to Imatinib Mesylate resistance. Identification of these mutations is important for treatment decisions and precision medicine in chronic myeloid leukaemia (CML). ABL1 T315I Recombinant Human Active Protein Kinase is a recombinant ABL1 T315I protein that can be used to study ABL1 T315I-related functions .

HY-E70638

**ABL1 M351T Recombinant Human Active Protein Kinase**	Bcr-Abl	Cancer
The emergence of mutations in the BCR::ABL1 kinase domain (KD) impairs Imatinib Mesylate (HY-50946) binding capacity, thus contributing to Imatinib Mesylate resistance. Identification of these mutations is important for treatment decisions and precision medicine in chronic myeloid leukaemia (CML). ABL1 M351T Recombinant Human Active Protein Kinase is a recombinant ABL1 M351T protein that can be used to study ABL1 M351T-related functions .

HY-E70635

**ABL1 F317I Recombinant Human Active Protein Kinase**	Bcr-Abl	Cancer
The emergence of mutations in the BCR::ABL1 kinase domain (KD) impairs Imatinib Mesylate (HY-50946) binding capacity, thus contributing to Imatinib Mesylate resistance. Identification of these mutations is important for treatment decisions and precision medicine in chronic myeloid leukaemia (CML). ABL1 F317I Recombinant Human Active Protein Kinase is a recombinant ABL1 F317I protein that can be used to study ABL1 F317I-related functions .

HY-E70641

**ABL1 Y253F Recombinant Human Active Protein Kinase**	Bcr-Abl	Cancer
The emergence of mutations in the BCR::ABL1 kinase domain (KD) impairs Imatinib Mesylate (HY-50946) binding capacity, thus contributing to Imatinib Mesylate resistance. Identification of these mutations is important for treatment decisions and precision medicine in chronic myeloid leukaemia (CML). ABL1 Y253F Recombinant Human Active Protein Kinase is a recombinant ABL1 Y253F protein that can be used to study ABL1 Y253F-related functions .

HY-E70636

**ABL1 G250E Recombinant Human Active Protein Kinase**	Bcr-Abl	Cancer
The emergence of mutations in the BCR::ABL1 kinase domain (KD) impairs Imatinib Mesylate (HY-50946) binding capacity, thus contributing to Imatinib Mesylate resistance. Identification of these mutations is important for treatment decisions and precision medicine in chronic myeloid leukaemia (CML). ABL1 G250E Recombinant Human Active Protein Kinase is a recombinant ABL1 G250E protein that can be used to study ABL1 G250E-related functions .

HY-E70637

**ABL1 H396P Recombinant Human Active Protein Kinase**	Bcr-Abl	Cancer
The emergence of mutations in the BCR::ABL1 kinase domain (KD) impairs Imatinib Mesylate (HY-50946) binding capacity, thus contributing to Imatinib Mesylate resistance. Identification of these mutations is important for treatment decisions and precision medicine in chronic myeloid leukaemia (CML). ABL1 H396P Recombinant Human Active Protein Kinase is a recombinant ABL1 H396P protein that can be used to study ABL1 H396P-related functions .

HY-13072R

Cenisertib (Standard) AS-703569 (Standard); R-763 (Standard)	Aurora Kinase Bcr-Abl Akt STAT FLT3 Reference Standards	Cancer
Cenisertib (Standard) is the analytical standard of Cenisertib. This product is intended for research and analytical applications. Cenisertib (AS-703569) is an ATP-competitive multi-kinase inhibitor that blocks the activity of Aurora-kinase-A/B, ABL1, AKT, STAT5 and FLT3. Cenisertib induces major growth-inhibitory effects by blocking the activity of several different molecular targets in neoplastic mast cells (MC). Cenisertib inhibits tumor growth in xenograft models of pancreatic, breast, colon, ovarian, and lung tumors and leukemia .

HY-18819

BCR-ABL-IN-2	Bcr-Abl	Cancer
BCR-ABL-IN-2 is an inhibitor of *BCR-ABL1* tyrosine kinase, with IC₅₀s of 57 nM, 773 nm for ABL1 ^native and ABL1 ^T315I, respectively.

HY-175281

SJ11646	PROTACs Src Discoidin Domain Receptor Bcr-Abl Apoptosis	Cancer
SJ11646 is a Dasatinib (HY-10181)-based LCK PROTAC degrader with a DC₅₀ of 0.00838 pM. SJ11646 has potent cytotoxicity against LCK-activated T-cell acute lymphoblastic leukemia (T-ALL) cells and primary leukemia samples with drastically prolonged suppression of LCK signaling, and induces T-ALL apoptosis. SJ11646 binds to 51 human kinases with a high affinity (particularly ABL1, KIT, and DDR1). SJ11646 has superior antileukemic efficacy in T-ALL mice model. . Pink: LCK ligand (HY-107447); Blue: CRBN ligase ligand (HY-163169); Black: linker (HY-76667)

HY-179247

BCR-ABL1-IN-2	Bcr-Abl	Cancer
BCR-ABL1-IN-2 (compound 8) is a potent BCR-ABL1 tyrosine kinase inhibitor. BCR-ABL1-IN-2 exhibits activity in Imatinib (HY-15463) resistant K562/DOX cells with LC₅₀ of 5.29 μM. BCR-ABL1-IN-2 shows no significant toxicity in nontumor cells. BCR-ABL1-IN-2 can be used for chronic myeloid leukemia research .

HY-171146

HSN748	FLT3 Bcr-Abl RET PDGFR MNK	Cancer
HSN748 is a Ponatinib (HY-12047) analogue and a multikinase inhibitor. HSN748 has inhibitory activity on FLT3, *ABL1, RET, PDGFRα/β, MNK1, MNK2* and other kinases. HSN748 can inhibit the growth of chronic myeloid leukemia and acute myeloid leukemia cell lines and can be used in the study of leukemia .

HY-162952

cSRC/BCR-ABL1-IN-1	Bcr-Abl	Cancer
cSRC/BCR-ABL1-IN-1 (compund 16a) is a dual-target *cSRC/BCR-ABL1* kinase inhibitor .

HY-101268

CHMFL-ABL-053	Bcr-Abl Src p38 MAPK	Cancer
CHMFL-ABL-053 (Compound 18a) is a potent, selective, and orally available *BCR-ABL, SRC* and p38 kinase inhibitor with IC₅₀ values of 70, 90 and 62 nM against ABL1, SRC and p38, respectively .

HY-162489

Tyrosine kinase-IN-8	Bcr-Abl	Others
Tyrosine kinase-IN-8 (compound 4e) is a *BCR‐ABL1* tyrosine kinase inhibitor (TKI). Tyrosine kinase-IN-8 shows anti-proliferative activity against K562 cells, a chronic myeloid leukemia (CML) cell line (CC₅₀=0.8 µM). Tyrosine kinase-IN-8 can be used in the study of chronic leukemia .

HY-13072B

Cenisertib benzoate AS-703569 benzoate; R-763 benzoate	Aurora Kinase Bcr-Abl Akt STAT FLT3	Cancer
Cenisertib (AS-703569) benzoate is an ATP-competitive multi-kinase inhibitor that blocks the activity of *Aurora-kinase-A/B, ABL1, AKT, STAT5 and FLT3*. Cenisertib benzoate induces major growth-inhibitory effects by blocking the activity of several different molecular targets in neoplastic mast cells (MC). Cenisertib benzoate inhibits tumor growth in xenograft models of pancreatic, breast, colon, ovarian, and lung tumors and leukemia .

HY-15728S

Radotinib-d6 IY-5511-d₆	Isotope-Labeled Compounds Bcr-Abl Apoptosis STAT JAK Prion Protein	Infection Neurological Disease Cancer
Radotinib-d₆ is deuterium labeled Radotinib (HY-15728). Radotinib (IY-5511) is an orally active and BBB-permeable selective tyrosine kinase *Bcr-Abl1* inhibitor with an IC₅₀ of 34 nM. Radotinib has anti-prion and anti-tumor activities. Radotinib can inhibit the proliferation, induce cell cycle arrest and apoptosis of tumor cells . Radotinib can be used in the research of cancer such as chronic myeloid leukemia and multiple myeloma, as well as neurodegenerative diseases such as prion diseases .

HY-185227

EphB4-IN-1	Ephrin Receptor Src Bcr-Abl EGFR	Cancer
EphB4-IN-1 is a selective EphB4 tyrosine kinase inhibitor with IC₅₀ values of 0.16-0.30 μM. EphB4-IN-1 binds to the ATP binding site of EphB4 in a DFG-in conformation, forming four stable intermolecular hydrogen bonds. EphB4-IN-1 also inhibits Src, *Abl1, Lck, and EGFR* kinases. EphB4-IN-1 inhibits EphB4 autophosphorylation. EphB4-IN-1 can be used for the research of cancer, such as non small cell lung cancer .

HY-119177

PD173956	Bcr-Abl	Others
PD173956 is a pyridopyrimidine Bcr-Abl kinase inhibitor with high selectivity for the P-loop mutant form of Bcr-Abl .

HY-181046

Multi-kinase-IN-14	α-synuclein Bcr-Abl GSK-3 DYRK LRRK2 Microtubule/Tubulin	Neurological Disease
Multi-kinase-IN-14 is an orally active and blood-brain barrier-permeable multi-kinase inhibitor. Multi-kinase-IN-14 reduces the excessive phosphorylation of α-synuclein by inhibiting four kinases (ABL1, DYRK1A, GSK3β, and LRRK2) and stabilizing microtubules. Multi-kinase-IN-14 is applicable for research on neurodegenerative diseases such as Parkinson’s disease and Alzheimer’s disease .

HY-179460

Radotinib dihydrochloride IY-5511 dihydrochloride	Bcr-Abl Apoptosis STAT JAK Prion Protein	Neurological Disease Cancer
Radotinib (IY-5511) dihydrochloride is an orally active and BBB-permeable selective tyrosine kinase *Bcr-Abl1* inhibitor with an IC₅₀ of 34 nM. Radotinib dihydrochloride has anti-prion and anti-tumor activities. Radotinib dihydrochloride can inhibit the proliferation, induce cell cycle arrest and apoptosis of tumor cells . Radotinib dihydrochloride can be used in the research of cancer such as chronic myeloid leukemia and multiple myeloma, as well as neurodegenerative diseases such as prion diseases .

HY-103032R

Multi-kinase inhibitor 1 (Standard)	Reference Standards PDGFR c-Kit Bcr-Abl	Cancer
Multi-kinase inhibitor 1 (Standard) is the analytical standard of Multi-kinase inhibitor 1 (HY-103032). This product is intended for research and analytical applications. Multi-kinase inhibitor 1 is a potent multi-kinase inhibitor. Multi-kinase inhibitor 1 has the potential for diseases or disorders associated with abnormal or deregulated tyrosine kinase activity, particularly diseases associated with the activity of PDGF-R, c-Kit and Bcr-abl .

HY-181839

DDR1/2 IN-4	Discoidin Domain Receptor	Inflammation/Immunology
DDR1/2 IN-4 (Compound 37) is a selective dual DDR1 and DDR2 kinase inhibitor, with a pK_i of 8.6 for DDR1 and a pK_i of 8.2 for DDR2. DDR1/2 IN-4 functionally inhibits the kinase activities of DDR1 and DDR2. DDR1/2 IN-4 inhibits the release of MCP-1. DDR1/2 IN-4 can be used in studies related to idiopathic pulmonary fibrosis .

HY-182792

Embibatinib TERN-701	Bcr-Abl	Cancer
Embibatinib (TERN-701) (Compound 1) is a highly selective, orally effective BCR-ABL allosteric inhibitor. Embibatinib is applicable for cancer research, particularly leukemia .

Species:	Human (6)
Tag:	Tag Free (4) GST (2)
Source:	sf9 insect cells (3) Sf9 insect cells (2) E. coli (1)

Cat. No.	Compare	Product Name	Species	Source	Image

HY-P71685

	ABL1 Protein, Human (GST) Abelson murine leukemia viral oncogene homolog 1; Abelson tyrosine protein kinase 1; ABL 1; ABL; JTK7; p150; Proto oncogene tyrosine protein kinase ABL1	Human	E. coli
	ABL1, Human (GST) is a non-receptor tyrosine-protein kinase. ABL1, Human is implicated in a wide range of cellular processes, including regulation of cell growth and survival, oxidative stress and DNA-damage responses, actin dynamics and cell migration, transmission of information about the cellular environment through integrin signaling.

HY-P702716

	ABL1 Protein, Human (Active, sf9) Abelson murine leukemia viral oncogene homolog 1; Abelson tyrosine protein kinase 1; ABL 1; ABL; JTK7; p150; Proto oncogene tyrosine protein kinase ABL1	Human	Sf9 insect cells
	ABL1 is a non-receptor tyrosine protein kinase that coordinates key cellular processes for growth and survival. It affects cytoskeletal remodeling, cell motility, and receptor endocytosis. ABL1 Protein, Human (sf9) is the recombinant human-derived ABL1, expressed by Sf9 insect cells, with tag-free. The total length of ABL1 Protein, Human (sf9) is 1104 a.a..

HY-P77308

	ABL1 Protein, Human (Active, sf9, GST) Abelson murine leukemia viral oncogene homolog 1; Abelson tyrosine protein kinase 1; ABL 1; ABL; JTK7; p150; Proto oncogene tyrosine protein kinase ABL1	Human	Sf9 insect cells
	ABL1 is a non-receptor tyrosine protein kinase that coordinates key cellular processes for growth and survival. It affects cytoskeletal remodeling, cell motility, and receptor endocytosis. ABL1 Protein, Human (sf9, GST) is the recombinant human-derived ABL1 protein, expressed by Sf9 insect cells , with N-GST labeled tag.

HY-P705723

	ABL1 Protein, Human (Active, Y245F, sf9) Abelson murine leukemia viral oncogene homolog 1; Abelson tyrosine protein kinase 1; ABL 1; ABL; JTK7; p150; Proto oncogene tyrosine protein kinase ABL1	Human	sf9 insect cells

HY-P705725

	ABL1 Protein, Human (Inactive, K290R, sf9) Abelson murine leukemia viral oncogene homolog 1; Abelson tyrosine protein kinase 1; ABL 1; ABL; JTK7; p150; Proto oncogene tyrosine protein kinase ABL1	Human	sf9 insect cells

HY-P705724

	ABL1 Protein, Human (Active, Y245F, Y412F, sf9) Abelson murine leukemia viral oncogene homolog 1; Abelson tyrosine protein kinase 1; ABL 1; ABL; JTK7; p150; Proto oncogene tyrosine protein kinase ABL1	Human	sf9 insect cells

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name	Chemical Structure

HY-15728S

Radotinib-d6
Radotinib-d₆ is deuterium labeled Radotinib (HY-15728). Radotinib (IY-5511) is an orally active and BBB-permeable selective tyrosine kinase *Bcr-Abl1* inhibitor with an IC₅₀ of 34 nM. Radotinib has anti-prion and anti-tumor activities. Radotinib can inhibit the proliferation, induce cell cycle arrest and apoptosis of tumor cells . Radotinib can be used in the research of cancer such as chronic myeloid leukemia and multiple myeloma, as well as neurodegenerative diseases such as prion diseases .

Radotinib-d6

Radotinib-d₆ is deuterium labeled Radotinib (HY-15728). Radotinib (IY-5511) is an orally active and BBB-permeable selective tyrosine kinase Bcr-Abl1 inhibitor with an IC₅₀ of 34 nM. Radotinib has anti-prion and anti-tumor activities. Radotinib can inhibit the proliferation, induce cell cycle arrest and apoptosis of tumor cells . Radotinib can be used in the research of cancer such as chronic myeloid leukemia and multiple myeloma, as well as neurodegenerative diseases such as prion diseases .

Host:	Rabbit (2)
Reactivity:	Human (2) Mouse (1)
Application:	IHC-P (2) ICC/IF (2) IP (1) WB (2) FC (1) ELISA (1)
Isotype:	IgG (1) IgG/Kappa (1)
Conjugation:	Non-conjugated (2)
Clonality:	Monoclonal (2) Recombinant (1)
Modification:	Unmodified (2)

Cat. No.	Compare	Product Name	Application	Reactivity	Image

HY-P85070

	ABL1 Antibody (YA4762) ABL1; ABL; JTK7; Tyrosine-protein kinase ABL1; Abelson murine leukemia viral oncogene homolog 1; Abelson tyrosine-protein kinase 1; Proto-oncogene c-ABL; p150	WB, IHC-P, ICC/IF, FC	Human, Mouse
	ABL1 Antibody (YA4762) is a Rabbit-derived and non-conjugated monoclonal antibody, targeting to ABL1.

HY-P86379

	ABL1 Antibody (YA6071) c-ABL; ABL1; ABL; JTK7; Tyrosine-protein kinase ABL1; Abelson murine leukemia viral oncogene homolog 1; Abelson tyrosine-protein kinase 1; Proto-oncogene c-ABL; p150;	WB, IHC-P, ICC/IF, IP, ELISA	Human
	ABL1 Antibody (YA6071) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to ABL1.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Host
Reactivity
Application
Dilution Ratio
Molecular Weight
Conjugation
Clonality
Immunogen
Appearance
Isotype
Gene ID
SwissProt ID
Purity
Formulation
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: